Research programme: NC1 inhibitors - BioStratumAlternative Names: NC1 inhibitors research programme - BioStratum
Latest Information Update: 28 Jan 2011
At a glance
- Originator BioStratum
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Jan 2011 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 06 Apr 2004 This programme is available for licensing (http://www.biostratum.com)
- 18 Jul 2003 Preclinical trials in Cancer in USA (unspecified route)